Next-Generation Artificial Pancreas System Launches

Medtronic’s New MiniMed®640G Artificial Pancreas System Predicts and Helps Prevent Deadly Low Glucose Emergencies A four year-old Australian boy with type 1 diabetes (T1D) is the first person to use a groundbreaking commercial artificial pancreas system that can predict and automatically prevent low blood-glucose emergencies. Medtronic’s MiniMed® 640G is an insulin pump/continuous glucose monitor combination […]

T1D Trial Looks to Teach an Old Drug New Tricks

JDRF-funded clinical study of a drug called TUDCA looks to improve beta cell functioning in people recently diagnosed with T1D Until recently, much of type 1 diabetes (T1D) research has focused on suppressing the autoimmune system to prevent or reverse disease, but this approach has been slow to yield promising, long-term results in people with […]

Re-educating the Immune System in T1D

JDRF partner Selecta developed a novel technology for creating a T1D vaccine to potentially halt the disease process It has been more than 30 years since scientists identified the basic autoimmune feature of type 1 diabetes (T1D) when they discovered autoantibodies binding to targets from cells in the pancreas. And yet, devising therapies to halt […]

Unlocking a Combination Therapy for New Onset T1D

A new study is further assessing if a novel combination of drugs could help treat new onset type 1 diabetes University of Florida researchers are ready to launch a new clinical study to examine if a combination of two U.S Food and Drug Administration (FDA) approved drugs, antithymocyte globulin (ATG) and granulocyte colony stimulating factor […]

JDRF General Research Progress Report for 2014-2015

JDRF General Research Progress Report for 2014-2015

It has often been said that the road to progress is rarely a straight line. At JDRF, we know nothing holds truer when it comes to progress in developing improved treatments and a cure for type 1 diabetes (T1D). This is why, with the generous help of our supporters, JDRF is pursuing a diversified, dynamic […]

Advancing a Key Artificial Pancreas Technology

Stable liquid glucagon developed by JDRF partner Xeris evaluated in first clinical study The JDRF Artificial Pancreas (AP) project is focused on accelerating the development of commercially-viable AP systems that better mimic the biological function of the pancreas and reduce the daily burden of managing type 1 diabetes (T1D). To achieve this goal, JDRF funds […]

Improving Beta Cell Health and Survival

JDRF-funded clinical study to test marketed drug to improve beta cell health and survival in T1D JDRF recently awarded a $2.1 million grant to Anath Shalev, M.D., director of the University of Alabama’s (UAB) Comprehensive Diabetes Center, to test the impact of a common blood pressure drug called verapamil on the health and survival of […]

Historic Progress for JDRF Encapsulation Research Program

First people with type 1 diabetes receive experimental encapsulated cell replacement therapies in clinical studies Two JDRF-funded partners have successfully implanted people with type 1 diabetes (T1D) with experimental encapsulated cell replacement therapies in clinical studies. These two programs are running in parallel and are evaluating two distinct encapsulation therapies. Encapsulated cell replacement therapy involves […]

It’s Time to Redefine Type 1 Diabetes

Last month, JDRF co-hosted a workshop where healthcare experts from government, nonprofit agencies and educational institutions discussed expanding the definition of Type 1 Diabetes (T1D) to recognize the earliest stages of human T1D before a person is clinically symptomatic. The benefits of the proposed system could include potentially faster drug development, identification of people living […]